查看購物車
  • English
  • Japanese
封面
市場調查報告書
商品編碼
1945275

2026年全球血液學和腫瘤學檢測市場報告

Hemato Oncology Testing Global Market Report 2026
出版日期: | 出版商: The Business Research Company | 英文 250 Pages | 商品交期: 2-10個工作天內

價格
簡介目錄

近年來，血液學和腫瘤學檢測市場發展迅速，預計將從2025年的39.3億美元成長到2026年的45億美元，複合年成長率達14.4%。過去幾年的成長可歸因於多種因素，包括血液系統癌症發病率的上升、醫院診斷檢查室的擴張、人們對癌症早期檢測意識提升、臨床研究活動的增加以及先進檢測試劑的廣泛應用。

預計未來幾年血液腫瘤檢測市場將快速成長，到2030年市場規模將達到77.6億美元，複合年成長率（CAGR）為14.6%。預測期內的成長要素包括精準腫瘤診斷技術的日益普及、基因組檢測基礎設施投資的增加、人工智慧驅動的診斷平台的擴展、伴隨診斷需求的成長以及檢測技術的持續創新。預測期內的關鍵趨勢包括分子診斷檢測技術的日益普及、次世代定序在腫瘤學領域的應用日益廣泛、個性化癌症診斷需求的成長、自動化檢測平台的擴展以及數據分析在血液腫瘤學領域日益增強的整合。

血液系統惡性腫瘤發生率的不斷上升預計將推動血液腫瘤檢測市場的成長。血液系統惡性腫瘤是指起源於血液、骨髓和淋巴系統的癌症，包括白血病、淋巴瘤和骨髓瘤等疾病。早期診斷對這些疾病至關重要，而血液腫瘤檢測在實現早期診斷方面發揮關鍵作用。例如，根據英國癌症研究中心（Cancer Research UK ）估計，截至2025年9月，英國白血病的發生率約為每年每10萬人17.9例，預計與2020年至2024年相比將呈下降趨勢。 2024年至2026年，英國白血病的發生率預計仍約為每年每10萬人17.9例，預計到2038年至2040年將下降3%，至約每10萬人17.4例。因此，血液腫瘤盛行率的上升是推動血液腫瘤檢測市場發展的關鍵因素。

血液學和腫瘤學檢測市場的主要企業正在引入諸如次世代定序(NGS) 等新技術，以提高基因分析的準確性和速度，實現對骨髓惡性腫瘤的全面分析，並支持針對個別患者需求的個人化治療策略。 NGS 是一種高通量DNA測序技術，能夠快速、經濟高效地分析整個基因組或特定 DNA 區域。例如，2024 年 10 月，專注於癌症診斷和基因組檢測的美國公司 NeoGenomics Inc. 推出了 AML Express，這是一款旨在快速檢測與急性骨髓性白血病(AML) 相關的突變的次世代定序工具。這款先進的診斷平台可提供高精度且快速的檢測結果，幫助腫瘤科醫師及時做出有針對性的治療決策。 AML Express 旨在透過提供 AML 特定基因譜的精準突變資訊來改善患者的治療效果。

目錄

第1章執行摘要

第2章 市場特徵

  • 市場定義和範圍
  • 市場區隔
  • 主要產品和服務概述
  • 全球血液學和腫瘤學檢測市場：吸引力評分和分析
  • 成長潛力分析、競爭評估、策略契合度評估、風險狀況評估

第3章 市場供應鏈分析

  • 供應鏈與生態系概述
  • 主要原料、資源和供應商清單
  • 主要經銷商和通路合作夥伴名單
  • 主要最終用戶列表

第4章 全球市場趨勢與策略

  • 關鍵技術和未來趨勢
    • 生物技術、基因組學和精準醫學
    • 人工智慧與自主智慧
    • 數位化、雲端運算、巨量資料、網路安全
    • 工業4.0和智慧製造
    • 物聯網 (IoT)、智慧基礎設施和互聯生態系統
  • 主要趨勢
    • 分子診斷檢測的應用日益廣泛
    • 腫瘤學中次世代定序的廣泛應用
    • 對個人化癌症診斷的需求日益成長
    • 擴展自動化測試平台
    • 加強血液學和腫瘤學中數據分析的整合

第5章 終端用戶產業市場分析

  • 醫院
  • 診斷檢查室
  • 學術研究機構
  • 腫瘤診所
  • CRO（受託研究機構）

第6章 市場：宏觀經濟情景，包括利率、通貨膨脹、地緣政治、貿易戰和關稅的影響、關稅戰和貿易保護主義對供應鏈的影響，以及新冠疫情對市場的影響

第7章 全球策略分析架構、目前市場規模、市場對比及成長率分析

  • 全球血液學和腫瘤學檢測市場：PESTEL 分析（政治、社會、技術、環境、法律因素、促進因素和限制因素）
  • 全球血液學及腫瘤學檢測市場規模、對比及成長率分析
  • 全球血液學和腫瘤學檢測市場表現：規模和成長，2020-2025年
  • 全球血液學和腫瘤學檢測市場預測：規模和成長，2025-2030年，2035年預測

第8章 全球潛在市場規模（TAM）

第9章 市場細分

  • 按產品/服務
  • 檢測試劑盒、試劑和服務
  • 癌症類型
  • 白血病、淋巴瘤、多發性骨髓瘤
  • 透過技術
  • 聚合酵素鏈鎖反應（PCR）、免疫組織化學（IHC）、次世代定序（NGS）
  • 最終用戶
  • 醫院、學術研究機構
  • 按類型細分：檢測試劑盒和試劑
  • PCR試劑盒、次世代定序（NGS）試劑盒、流式細胞技術試劑、抗體
  • 按類型細分：服務
  • 測試服務、數據分析服務

第10章 區域與國家分析

  • 全球血液學及腫瘤學檢測市場：區域表現及預測，2020-2025年、2025-2030年預測、2035年預測
  • 全球血液學和腫瘤學檢測市場：按國家/地區、績效和預測分類，2020-2025年、2025-2030年預測、2035年預測

第11章 亞太市場

第12章：中國市場

第13章 印度市場

第14章 日本市場

第15章：澳洲市場

第16章 印尼市場

第17章 韓國市場

第18章 台灣市場

第19章 東南亞市場

第20章：西歐市場

第21章英國市場

第22章 德國市場

第23章：法國市場

第24章：義大利市場

第25章：西班牙市場

第26章 東歐市場

第27章：俄羅斯市場

第28章 北美市場

第29章：美國市場

第30章：加拿大市場

第31章 南美洲市場

第32章：巴西市場

第33章 中東市場

第34章：非洲市場

第35章 市場監理與投資環境

第36章：競爭格局與公司概況

  • 血液學和腫瘤學檢測市場：競爭格局和市場佔有率，2024 年
  • 血液學和腫瘤學檢測市場：公司估值矩陣
  • 血液學和腫瘤學檢測市場：公司概況
    • F. Hoffmann-La Roche Ltd.
    • Abbott Laboratories
    • Thermo Fisher Scientific Inc.
    • Illumina Inc.
    • Invivoscribe Inc.

第37章：其他領先和創新企業

  • Qiagen NV, Bio-Rad Laboratories Inc., Archerdx Inc., ARUP Laboratories Inc., Asuragen Inc., Adaptive Biotechnologies Corp., Cepheid Inc., EntroGen Inc., CORE Diagnostics Inc., Genoptix Inc., GenPath Diagnostics, NeoGenomics Laboratories Inc., Siemens AG, Sysmex Corporation, Laboratory Corporation of America Holdings

第38章 全球市場競爭基準分析與儀錶板

第39章 重大併購

第40章：高潛力市場國家、細分市場與策略

  • 2030年血液學和腫瘤學檢測市場：提供新機會的國家
  • 2030年血液學和腫瘤學檢測市場：充滿新機會的細分市場
  • 2030年血液學和腫瘤學檢測市場：成長策略
    • 基於市場趨勢的策略
    • 競爭對手策略

第41章附錄

簡介目錄
Product Code: ME3MHOTN01_G26Q1

Hemato-oncology testing involves diagnostic procedures designed to identify symptoms of blood disorders and blood cancers. These tests play a crucial role in diagnosing conditions such as anemia, infections, hemophilia, blood-clotting disorders, and leukemia.

The primary products and services associated with hemato-oncology testing include assay kits, reagents, and testing services. Assay kits and reagents encompass instruments and chemicals utilized together to analyze specific substances. The testing procedures cover various cancer types, including leukemia, lymphoma, multiple myeloma, and others. The technologies employed for these tests include polymerase chain reaction (PCR), immunohistochemistry (IHC), next-generation sequencing (NGS), and other advanced techniques. The end-users of hemato-oncology testing include hospitals, academic and research institutes, and other healthcare entities.

Tariffs are influencing the hemato oncology testing market by increasing costs of imported reagents, sequencing instruments, laboratory automation systems, and analytical software components. Diagnostic laboratories and hospitals in North America and Europe are most affected due to dependence on imported high-end testing equipment, while Asia-Pacific faces cost pressures on reagent manufacturing and export. These tariffs are raising operational expenses and test pricing. However, they are also promoting domestic reagent production, regional equipment manufacturing, and localized development of diagnostic technologies.

The hemato oncology testing market research report is one of a series of new reports from The Business Research Company that provides hemato oncology testing market statistics, including hemato oncology testing industry global market size, regional shares, competitors with a hemato oncology testing market share, detailed hemato oncology testing market segments, market trends and opportunities, and any further data you may need to thrive in the hemato oncology testing industry. This hemato oncology testing market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

The hemato oncology testing market size has grown rapidly in recent years. It will grow from $3.93 billion in 2025 to $4.5 billion in 2026 at a compound annual growth rate (CAGR) of 14.4%. The growth in the historic period can be attributed to rising incidence of blood cancers, expansion of hospital diagnostic laboratories, increasing awareness of early cancer detection, growth in clinical research activities, availability of advanced testing reagents.

The hemato oncology testing market size is expected to see rapid growth in the next few years. It will grow to $7.76 billion in 2030 at a compound annual growth rate (CAGR) of 14.6%. The growth in the forecast period can be attributed to increasing adoption of precision oncology diagnostics, rising investments in genomic testing infrastructure, expansion of AI-driven diagnostic platforms, growing demand for companion diagnostics, continuous innovation in assay technologies. Major trends in the forecast period include increasing adoption of molecular diagnostic testing, rising use of next-generation sequencing in oncology, growing demand for personalized cancer diagnostics, expansion of automated laboratory testing platforms, enhanced integration of data analytics in hemato-oncology.

The anticipated rise in the incidence of hematologic cancer is set to be a driving force behind the growth of the hemato-oncology testing market. Hematologic cancer encompasses a group of cancers originating in the blood, affecting the blood, bone marrow, and lymphatic system, including conditions such as leukemia, lymphoma, and myeloma. Early diagnosis is crucial for these diseases, and hemato-oncology testing plays a pivotal role in achieving this. For instance, in September 2025, according to Cancer Research UK, a UK-based charity, From 2024 to 2026, the incidence rate of leukemia in the UK is estimated at approximately 17.9 cases per 100,000 people per year, and it is projected to decrease by 3% to around 17.4 per 100,000 by 2038 to 2040. Hence, the increasing prevalence of hematologic cancers is a significant driver propelling the hemato-oncology testing market forward.

Key companies in the hemato-oncology testing market are implementing new innovations such as next-generation sequencing (NGS) to enhance the accuracy and speed of genetic analysis, enable comprehensive profiling of hematologic malignancies, and support personalized treatment strategies tailored to the needs of individual patients. NGS is a high-throughput DNA sequencing technology that facilitates rapid and cost-effective analysis of entire genomes or specific DNA regions. For example, in October 2024, NeoGenomics Inc., a U.S.-based company specializing in cancer diagnostics and genomic testing, launched AML Express, a next-generation sequencing tool designed for the swift detection of mutations related to Acute Myeloid Leukemia (AML). This advanced diagnostic platform provides high accuracy and quick turnaround times, assisting oncologists in making timely and targeted treatment decisions. AML Express aims to enhance patient outcomes by delivering precise mutation insights tailored to the specific genetic profiles associated with AML.

In January 2023, Merck & Co. Inc., a leading US-based pharmaceutical company, acquired Imago BioSciences, Inc., a biotechnology company focusing on diagnostic and therapeutic products for hemato-oncology testing and related blood disorders. This acquisition aligns with Merck's commitment to fortify its presence in the hematology field by investing in innovative solutions and strengthening its pipeline.

Major companies operating in the hemato oncology testing market are F. Hoffmann-La Roche Ltd., Abbott Laboratories, Thermo Fisher Scientific Inc., Illumina Inc., Invivoscribe Inc., Qiagen N.V., Bio-Rad Laboratories Inc., Archerdx Inc., ARUP Laboratories Inc., Asuragen Inc., Adaptive Biotechnologies Corp., Cepheid Inc., EntroGen Inc., CORE Diagnostics Inc., Genoptix Inc., GenPath Diagnostics, NeoGenomics Laboratories Inc., Siemens AG, Sysmex Corporation, Laboratory Corporation of America Holdings, Agilent Technologies, Danaher Corporation, Grifols SA, Diaorin SpA, HTG Molecular Diagnostics Inc., Admera Health

North America was the largest region in the hemato oncology testing market in 2025. Asia-Pacific is expected to be the fastest-growing region in the global hemato oncology testing market report during the forecast period. The regions covered in the hemato oncology testing market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

The countries covered in the hemato oncology testing market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Taiwan, Russia, South Korea, UK, USA, Canada, Italy, Spain

The hemato oncology testing market consists of revenues earned by entities by providing sampling and diagnostic services. The market value includes the value of related goods sold by the service provider or included within the service offering. The hemato-oncology testing market also includes the sales of consumables and instruments which are used to provide hemato-oncology testing services. Values in this market are 'factory gate' values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

Hemato Oncology Testing Market Global Report 2026 from The Business Research Company provides strategists, marketers and senior management with the critical information they need to assess the market.

This report focuses hemato oncology testing market which is experiencing strong growth. The report gives a guide to the trends which will be shaping the market over the next ten years and beyond.

Reasons to Purchase

  • Gain a truly global perspective with the most comprehensive report available on this market covering 16 geographies.
  • Assess the impact of key macro factors such as geopolitical conflicts, trade policies and tariffs, inflation and interest rate fluctuations, and evolving regulatory landscapes.
  • Create regional and country strategies on the basis of local data and analysis.
  • Identify growth segments for investment.
  • Outperform competitors using forecast data and the drivers and trends shaping the market.
  • Understand customers based on end user analysis.
  • Benchmark performance against key competitors based on market share, innovation, and brand strength.
  • Evaluate the total addressable market (TAM) and market attractiveness scoring to measure market potential.
  • Suitable for supporting your internal and external presentations with reliable high-quality data and analysis
  • Report will be updated with the latest data and delivered to you within 2-3 working days of order along with an Excel data sheet for easy data extraction and analysis.
  • All data from the report will also be delivered in an excel dashboard format.

Where is the largest and fastest growing market for hemato oncology testing ? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward, including technological disruption, regulatory shifts, and changing consumer preferences? The hemato oncology testing market global report from the Business Research Company answers all these questions and many more.

The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, total addressable market (TAM), market attractiveness score (MAS), competitive landscape, market shares, company scoring matrix, trends and strategies for this market. It traces the market's historic and forecast market growth by geography.

  • The market characteristics section of the report defines and explains the market. This section also examines key products and services offered in the market, evaluates brand-level differentiation, compares product features, and highlights major innovation and product development trends.
  • The supply chain analysis section provides an overview of the entire value chain, including key raw materials, resources, and supplier analysis. It also provides a list competitor at each level of the supply chain.
  • The updated trends and strategies section analyses the shape of the market as it evolves and highlights emerging technology trends such as digital transformation, automation, sustainability initiatives, and AI-driven innovation. It suggests how companies can leverage these advancements to strengthen their market position and achieve competitive differentiation.
  • The regulatory and investment landscape section provides an overview of the key regulatory frameworks, regularity bodies, associations, and government policies influencing the market. It also examines major investment flows, incentives, and funding trends shaping industry growth and innovation.
  • The market size section gives the market size ($b) covering both the historic growth of the market, and forecasting its development.
  • The forecasts are made after considering the major factors currently impacting the market. These include the technological advancements such as AI and automation, Russia-Ukraine war, trade tariffs (government-imposed import/export duties), elevated inflation and interest rates.
  • The total addressable market (TAM) analysis section defines and estimates the market potential compares it with the current market size, and provides strategic insights and growth opportunities based on this evaluation.
  • The market attractiveness scoring section evaluates the market based on a quantitative scoring framework that considers growth potential, competitive dynamics, strategic fit, and risk profile. It also provides interpretive insights and strategic implications for decision-makers.
  • Market segmentations break down the market into sub markets.
  • The regional and country breakdowns section gives an analysis of the market in each geography and the size of the market by geography and compares their historic and forecast growth.
  • Expanded geographical coverage includes Taiwan and Southeast Asia, reflecting recent supply chain realignments and manufacturing shifts in the region. This section analyzes how these markets are becoming increasingly important hubs in the global value chain.
  • The competitive landscape chapter gives a description of the competitive nature of the market, market shares, and a description of the leading companies. Key financial deals which have shaped the market in recent years are identified.
  • The company scoring matrix section evaluates and ranks leading companies based on a multi-parameter framework that includes market share or revenues, product innovation, and brand recognition.

Scope

  • Markets Covered:1) By Product And Services: Assay Kits And Reagents; Services
  • 2) By Cancer Type: Leukemia; Lymphoma; Multiple Myeloma
  • 3) By Technology: Polymerase Chain Reaction (PCR); Immunohistochemistry (IHC); Next-Generation Sequencing (NGS)
  • 4) By End User: Hospitals; Academic And Research Institutes
  • Subsegments:
  • 1) By Assay Kits And Reagents: PCR Kits; Next-Generation Sequencing (NGS) Kits; Flow Cytometry Reagents; Antibodies
  • 2) By Services: Testing Services; Data Analysis Services
  • Companies Mentioned: F. Hoffmann-La Roche Ltd.; Abbott Laboratories; Thermo Fisher Scientific Inc.; Illumina Inc.; Invivoscribe Inc.; Qiagen N.V.; Bio-Rad Laboratories Inc.; Archerdx Inc.; ARUP Laboratories Inc.; Asuragen Inc.; Adaptive Biotechnologies Corp.; Cepheid Inc.; EntroGen Inc.; CORE Diagnostics Inc.; Genoptix Inc.; GenPath Diagnostics; NeoGenomics Laboratories Inc.; Siemens AG; Sysmex Corporation; Laboratory Corporation of America Holdings; Agilent Technologies; Danaher Corporation; Grifols SA; Diaorin SpA; HTG Molecular Diagnostics Inc.; Admera Health
  • Countries: Australia; Brazil; China; France; Germany; India; Indonesia; Japan; Taiwan; Russia; South Korea; UK; USA; Canada; Italy; Spain
  • Regions: Asia-Pacific; South East Asia; Western Europe; Eastern Europe; North America; South America; Middle East; Africa
  • Time Series: Five years historic and ten years forecast.
  • Data: Ratios of market size and growth to related markets, GDP proportions, expenditure per capita,
  • Data Segmentations: country and regional historic and forecast data, market share of competitors, market segments.
  • Sourcing and Referencing: Data and analysis throughout the report is sourced using end notes.
  • Delivery Format: Word, PDF or Interactive Report
  • + Excel Dashboard
  • Added Benefits
  • Bi-Annual Data Update
  • Customisation
  • Expert Consultant Support

Added Benefits available all on all list-price licence purchases, to be claimed at time of purchase. Customisations within report scope and limited to 20% of content and consultant support time limited to 8 hours.

Table of Contents

1. Executive Summary

  • 1.1. Key Market Insights (2020-2035)
  • 1.2. Visual Dashboard: Market Size, Growth Rate, Hotspots
  • 1.3. Major Factors Driving the Market
  • 1.4. Top Three Trends Shaping the Market

2. Hemato Oncology Testing Market Characteristics

  • 2.1. Market Definition & Scope
  • 2.2. Market Segmentations
  • 2.3. Overview of Key Products and Services
  • 2.4. Global Hemato Oncology Testing Market Attractiveness Scoring And Analysis
    • 2.4.1. Overview of Market Attractiveness Framework
    • 2.4.2. Quantitative Scoring Methodology
    • 2.4.3. Factor-Wise Evaluation
  • Growth Potential Analysis, Competitive Dynamics Assessment, Strategic Fit Assessment And Risk Profile Evaluation
    • 2.4.4. Market Attractiveness Scoring and Interpretation
    • 2.4.5. Strategic Implications and Recommendations

3. Hemato Oncology Testing Market Supply Chain Analysis

  • 3.1. Overview of the Supply Chain and Ecosystem
  • 3.2. List Of Key Raw Materials, Resources & Suppliers
  • 3.3. List Of Major Distributors and Channel Partners
  • 3.4. List Of Major End Users

4. Global Hemato Oncology Testing Market Trends And Strategies

  • 4.1. Key Technologies & Future Trends
    • 4.1.1 Biotechnology, Genomics And Precision Medicine
    • 4.1.2 Artificial Intelligence And Autonomous Intelligence
    • 4.1.3 Digitalization, Cloud, Big Data And Cybersecurity
    • 4.1.4 Industry 4.0 And Intelligent Manufacturing
    • 4.1.5 Internet Of Things (Iot), Smart Infrastructure And Connected Ecosystems
  • 4.2. Major Trends
    • 4.2.1 Increasing Adoption Of Molecular Diagnostic Testing
    • 4.2.2 Rising Use Of Next-Generation Sequencing In Oncology
    • 4.2.3 Growing Demand For Personalized Cancer Diagnostics
    • 4.2.4 Expansion Of Automated Laboratory Testing Platforms
    • 4.2.5 Enhanced Integration Of Data Analytics In Hemato-Oncology

5. Hemato Oncology Testing Market Analysis Of End Use Industries

  • 5.1 Hospitals
  • 5.2 Diagnostic Laboratories
  • 5.3 Academic And Research Institutes
  • 5.4 Oncology Specialty Clinics
  • 5.5 Contract Research Organizations

6. Hemato Oncology Testing Market - Macro Economic Scenario Including The Impact Of Interest Rates, Inflation, Geopolitics, Trade Wars and Tariffs, Supply Chain Impact from Tariff War & Trade Protectionism, And Covid And Recovery On The Market

7. Global Hemato Oncology Testing Strategic Analysis Framework, Current Market Size, Market Comparisons And Growth Rate Analysis

  • 7.1. Global Hemato Oncology Testing PESTEL Analysis (Political, Social, Technological, Environmental and Legal Factors, Drivers and Restraints)
  • 7.2. Global Hemato Oncology Testing Market Size, Comparisons And Growth Rate Analysis
  • 7.3. Global Hemato Oncology Testing Historic Market Size and Growth, 2020 - 2025, Value ($ Billion)
  • 7.4. Global Hemato Oncology Testing Forecast Market Size and Growth, 2025 - 2030, 2035F, Value ($ Billion)

8. Global Hemato Oncology Testing Total Addressable Market (TAM) Analysis for the Market

  • 8.1. Definition and Scope of Total Addressable Market (TAM)
  • 8.2. Methodology and Assumptions
  • 8.3. Global Total Addressable Market (TAM) Estimation
  • 8.4. TAM vs. Current Market Size Analysis
  • 8.5. Strategic Insights and Growth Opportunities from TAM Analysis

9. Hemato Oncology Testing Market Segmentation

  • 9.1. Global Hemato Oncology Testing Market, Segmentation By Product And Services, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
  • Assay Kits And Reagents, Services
  • 9.2. Global Hemato Oncology Testing Market, Segmentation By Cancer Type, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
  • Leukemia, Lymphoma, Multiple Myeloma
  • 9.3. Global Hemato Oncology Testing Market, Segmentation By Technology, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
  • Polymerase Chain Reaction (PCR), Immunohistochemistry (IHC), Next-Generation Sequencing (NGS)
  • 9.4. Global Hemato Oncology Testing Market, Segmentation By End User, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
  • Hospitals, Academic And Research Institutes
  • 9.5. Global Hemato Oncology Testing Market, Sub-Segmentation Of Assay Kits And Reagents, By Type, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
  • PCR Kits, Next-Generation Sequencing (NGS) Kits, Flow Cytometry Reagents, Antibodies
  • 9.6. Global Hemato Oncology Testing Market, Sub-Segmentation Of Services, By Type, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
  • Testing Services, Data Analysis Services

10. Hemato Oncology Testing Market Regional And Country Analysis

  • 10.1. Global Hemato Oncology Testing Market, Split By Region, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
  • 10.2. Global Hemato Oncology Testing Market, Split By Country, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

11. Asia-Pacific Hemato Oncology Testing Market

  • 11.1. Asia-Pacific Hemato Oncology Testing Market Overview
  • Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
  • 11.2. Asia-Pacific Hemato Oncology Testing Market, Segmentation By Product And Services, Segmentation By Cancer Type, Segmentation By Technology, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

12. China Hemato Oncology Testing Market

  • 12.1. China Hemato Oncology Testing Market Overview
  • Country Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
  • 12.2. China Hemato Oncology Testing Market, Segmentation By Product And Services, Segmentation By Cancer Type, Segmentation By Technology, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

13. India Hemato Oncology Testing Market

  • 13.1. India Hemato Oncology Testing Market, Segmentation By Product And Services, Segmentation By Cancer Type, Segmentation By Technology, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

14. Japan Hemato Oncology Testing Market

  • 14.1. Japan Hemato Oncology Testing Market Overview
  • Country Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
  • 14.2. Japan Hemato Oncology Testing Market, Segmentation By Product And Services, Segmentation By Cancer Type, Segmentation By Technology, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

15. Australia Hemato Oncology Testing Market

  • 15.1. Australia Hemato Oncology Testing Market, Segmentation By Product And Services, Segmentation By Cancer Type, Segmentation By Technology, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

16. Indonesia Hemato Oncology Testing Market

  • 16.1. Indonesia Hemato Oncology Testing Market, Segmentation By Product And Services, Segmentation By Cancer Type, Segmentation By Technology, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

17. South Korea Hemato Oncology Testing Market

  • 17.1. South Korea Hemato Oncology Testing Market Overview
  • Country Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
  • 17.2. South Korea Hemato Oncology Testing Market, Segmentation By Product And Services, Segmentation By Cancer Type, Segmentation By Technology, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

18. Taiwan Hemato Oncology Testing Market

  • 18.1. Taiwan Hemato Oncology Testing Market Overview
  • Country Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
  • 18.2. Taiwan Hemato Oncology Testing Market, Segmentation By Product And Services, Segmentation By Cancer Type, Segmentation By Technology, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

19. South East Asia Hemato Oncology Testing Market

  • 19.1. South East Asia Hemato Oncology Testing Market Overview
  • Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
  • 19.2. South East Asia Hemato Oncology Testing Market, Segmentation By Product And Services, Segmentation By Cancer Type, Segmentation By Technology, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

20. Western Europe Hemato Oncology Testing Market

  • 20.1. Western Europe Hemato Oncology Testing Market Overview
  • Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
  • 20.2. Western Europe Hemato Oncology Testing Market, Segmentation By Product And Services, Segmentation By Cancer Type, Segmentation By Technology, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

21. UK Hemato Oncology Testing Market

  • 21.1. UK Hemato Oncology Testing Market, Segmentation By Product And Services, Segmentation By Cancer Type, Segmentation By Technology, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

22. Germany Hemato Oncology Testing Market

  • 22.1. Germany Hemato Oncology Testing Market, Segmentation By Product And Services, Segmentation By Cancer Type, Segmentation By Technology, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

23. France Hemato Oncology Testing Market

  • 23.1. France Hemato Oncology Testing Market, Segmentation By Product And Services, Segmentation By Cancer Type, Segmentation By Technology, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

24. Italy Hemato Oncology Testing Market

  • 24.1. Italy Hemato Oncology Testing Market, Segmentation By Product And Services, Segmentation By Cancer Type, Segmentation By Technology, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

25. Spain Hemato Oncology Testing Market

  • 25.1. Spain Hemato Oncology Testing Market, Segmentation By Product And Services, Segmentation By Cancer Type, Segmentation By Technology, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

26. Eastern Europe Hemato Oncology Testing Market

  • 26.1. Eastern Europe Hemato Oncology Testing Market Overview
  • Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
  • 26.2. Eastern Europe Hemato Oncology Testing Market, Segmentation By Product And Services, Segmentation By Cancer Type, Segmentation By Technology, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

27. Russia Hemato Oncology Testing Market

  • 27.1. Russia Hemato Oncology Testing Market, Segmentation By Product And Services, Segmentation By Cancer Type, Segmentation By Technology, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

28. North America Hemato Oncology Testing Market

  • 28.1. North America Hemato Oncology Testing Market Overview
  • Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
  • 28.2. North America Hemato Oncology Testing Market, Segmentation By Product And Services, Segmentation By Cancer Type, Segmentation By Technology, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

29. USA Hemato Oncology Testing Market

  • 29.1. USA Hemato Oncology Testing Market Overview
  • Country Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
  • 29.2. USA Hemato Oncology Testing Market, Segmentation By Product And Services, Segmentation By Cancer Type, Segmentation By Technology, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

30. Canada Hemato Oncology Testing Market

  • 30.1. Canada Hemato Oncology Testing Market Overview
  • Country Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
  • 30.2. Canada Hemato Oncology Testing Market, Segmentation By Product And Services, Segmentation By Cancer Type, Segmentation By Technology, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

31. South America Hemato Oncology Testing Market

  • 31.1. South America Hemato Oncology Testing Market Overview
  • Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
  • 31.2. South America Hemato Oncology Testing Market, Segmentation By Product And Services, Segmentation By Cancer Type, Segmentation By Technology, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

32. Brazil Hemato Oncology Testing Market

  • 32.1. Brazil Hemato Oncology Testing Market, Segmentation By Product And Services, Segmentation By Cancer Type, Segmentation By Technology, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

33. Middle East Hemato Oncology Testing Market

  • 33.1. Middle East Hemato Oncology Testing Market Overview
  • Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
  • 33.2. Middle East Hemato Oncology Testing Market, Segmentation By Product And Services, Segmentation By Cancer Type, Segmentation By Technology, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

34. Africa Hemato Oncology Testing Market

  • 34.1. Africa Hemato Oncology Testing Market Overview
  • Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
  • 34.2. Africa Hemato Oncology Testing Market, Segmentation By Product And Services, Segmentation By Cancer Type, Segmentation By Technology, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

35. Hemato Oncology Testing Market Regulatory and Investment Landscape

36. Hemato Oncology Testing Market Competitive Landscape And Company Profiles

  • 36.1. Hemato Oncology Testing Market Competitive Landscape And Market Share 2024
    • 36.1.1. Top 10 Companies (Ranked by revenue/share)
  • 36.2. Hemato Oncology Testing Market - Company Scoring Matrix
    • 36.2.1. Market Revenues
    • 36.2.2. Product Innovation Score
    • 36.2.3. Brand Recognition
  • 36.3. Hemato Oncology Testing Market Company Profiles
    • 36.3.1. F. Hoffmann-La Roche Ltd. Overview, Products and Services, Strategy and Financial Analysis
    • 36.3.2. Abbott Laboratories Overview, Products and Services, Strategy and Financial Analysis
    • 36.3.3. Thermo Fisher Scientific Inc. Overview, Products and Services, Strategy and Financial Analysis
    • 36.3.4. Illumina Inc. Overview, Products and Services, Strategy and Financial Analysis
    • 36.3.5. Invivoscribe Inc. Overview, Products and Services, Strategy and Financial Analysis

37. Hemato Oncology Testing Market Other Major And Innovative Companies

  • Qiagen N.V., Bio-Rad Laboratories Inc., Archerdx Inc., ARUP Laboratories Inc., Asuragen Inc., Adaptive Biotechnologies Corp., Cepheid Inc., EntroGen Inc., CORE Diagnostics Inc., Genoptix Inc., GenPath Diagnostics, NeoGenomics Laboratories Inc., Siemens AG, Sysmex Corporation, Laboratory Corporation of America Holdings

38. Global Hemato Oncology Testing Market Competitive Benchmarking And Dashboard

39. Key Mergers And Acquisitions In The Hemato Oncology Testing Market

40. Hemato Oncology Testing Market High Potential Countries, Segments and Strategies

  • 40.1 Hemato Oncology Testing Market In 2030 - Countries Offering Most New Opportunities
  • 40.2 Hemato Oncology Testing Market In 2030 - Segments Offering Most New Opportunities
  • 40.3 Hemato Oncology Testing Market In 2030 - Growth Strategies
    • 40.3.1 Market Trend Based Strategies
    • 40.3.2 Competitor Strategies

41. Appendix

  • 41.1. Abbreviations
  • 41.2. Currencies
  • 41.3. Historic And Forecast Inflation Rates
  • 41.4. Research Inquiries
  • 41.5. The Business Research Company
  • 41.6. Copyright And Disclaimer